This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment and prevention

Authoring team

Seek expert advice.

  • acute infections may be treated with tetracycline, doxycycline or erythromycin. Several courses may be necessary and the maximum effect of therapy may not be achieved for 10-12 weeks. Secondary scarring requires plastic surgery
  • single oral dose of azithromycin is as effective as 6 weeks of topical tetracycline (1)
  • in active trachoma, azithromycin eye drops twice daily for 2 or 3 days are as efficient as oral azithromycin (2)

  • the underlying conditions of poverty, overcrowding and poor hygiene must be alleviated. It is valuable to trace all family members who may have been in contact with the patient since they may harbour the disease. The use of prophylactic topical antibiotics is recommended

"SAFE" strategy for the control of trachoma (SAFE :strategy to eliminate trachoma by the year 2020 (WHO objective)):

  • Surgery for in-turned lashes
  • Antibiotics for active infection
  • Facial cleanliness
  • Environmental improvement

Reference:

  1. Mabey DC et al.Trachoma.Lancet. 2003 Jul 19;362(9379):223-9.
  2. Br J Ophthalmol. 2007 May;91(5):667-72.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.